Valpromide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H584466

CAS#: 2430-27-5

Description: Valpromide is an antiepileptic drug, derivative of Valproic acid (VPA), used as a mood-stabilizer in bipolar disorder.


Chemical Structure

img
Valpromide
CAS# 2430-27-5

Theoretical Analysis

Hodoodo Cat#: H584466
Name: Valpromide
CAS#: 2430-27-5
Chemical Formula: C8H17NO
Exact Mass: 143.13
Molecular Weight: 143.230
Elemental Analysis: C, 67.09; H, 11.96; N, 9.78; O, 11.17

Price and Availability

Size Price Availability Quantity
100mg USD 280
Bulk inquiry

Synonym: Valpromide; Depamide

IUPAC/Chemical Name: 2-propylpentanamide

InChi Key: OMOMUFTZPTXCHP-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)

SMILES Code: CCCC(CCC)C(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 143.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wieser HG. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res. 1991 Jul;9(2):154-9. PubMed PMID: 1794353.

2: Vandel S, Bertschy G, Jounet JM, Allers G. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit. 1988;10(4):386-9. PubMed PMID: 3144066.

3: Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, Wilensky AJ, Levy RH. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther. 1989 Jul;46(1):82-93. Erratum in: Clin Pharmacol Ther 1989 Sep;46(3):343. PubMed PMID: 2501059.

4: Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol. 1984;27(4):501-3. PubMed PMID: 6440792.

5: Payen C, Frantz P, Martin O, Parant F, Moulsma M, Pulce C, Descotes J. Delayed toxicity following acute ingestion of valpromide. Hum Exp Toxicol. 2004 Mar;23(3):145-8. PubMed PMID: 15119534.

6: Bialer M, Hadad S, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, Herzig Y, Yagen B. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide. Pharm Res. 1996 Feb;13(2):284-9. PubMed PMID: 8932450.

7: Gabriel L, Darcissac C, Goutelle S, Sève P, Vial T, de La Gastine B. [Lower limb edema during valpromide treatment: case report and literature review]. Rev Med Interne. 2015 Oct;36(10):698-700. doi: 10.1016/j.revmed.2014.11.011. Epub 2014 Dec 24. Review. French. PubMed PMID: 25544148.

8: Bourrier P, Varache N, Alquier P, Rabier D, Kamoun P, Lorre G, Alhayek G. [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase]. Presse Med. 1988 Nov 5;17(39):2063-6. French. PubMed PMID: 2974563.

9: Bialer M, Rubinstein A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharm Drug Dispos. 1984 Apr-Jun;5(2):177-83. PubMed PMID: 6430363.

10: Lemoine P, Fondarai J, Faivre T. Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and unipolar disorders. A placebo-controlled study. Eur Psychiatry. 2000 Nov;15(7):424-32. PubMed PMID: 11112935.

11: Margiotta N, Denora N, Piccinonna S, Laquintana V, Lasorsa FM, Franco M, Natile G. Synthesis, characterization, and in vitro evaluation of new coordination complexes of platinum(II) and rhenium(I) with a ligand targeting the translocator protein (TSPO). Dalton Trans. 2014 Nov 21;43(43):16252-64. doi: 10.1039/c4dt01540a. PubMed PMID: 25069996.

12: Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet. 1991 Feb;20(2):114-22. Review. PubMed PMID: 2029804.

13: Lambert PA, Venaud G. [Use of valpromide in psychiatric therapeutics]. Encephale. 1987 Nov-Dec;13(6):367-73. French. PubMed PMID: 3131112.

14: Paradis FH, Hales BF. Valproic Acid Induces the Hyperacetylation of P53, Expression of P53 Target Genes, and Markers of the Intrinsic Apoptotic Pathway in Midorganogenesis Murine Limbs. Birth Defects Res B Dev Reprod Toxicol. 2015 Oct;104(5):177-83. doi: 10.1002/bdrb.21149. Epub 2015 Aug 25. PubMed PMID: 26305274.

15: Pisani F, Fazio A, Oteri G, Spina E, Perucca E, Bertilsson L. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. Br J Clin Pharmacol. 1988 May;25(5):611-3. PubMed PMID: 3136790; PubMed Central PMCID: PMC1386437.

16: Pacifici GM, Temellini A, Giuliani L, Rane A, Thomas H, Oesch F. Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase. Arch Toxicol. 1989;63(2):157-9. PubMed PMID: 2499297.

17: Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res. 1998 Mar;30(1):41-8. PubMed PMID: 9551843.

18: Lindekens H, Smolders I, Khan GM, Bialer M, Ebinger G, Michotte Y. In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. Pharm Res. 2000 Nov;17(11):1408-13. PubMed PMID: 11205735.

19: Pokrajac M, Miljković B, Spiridonović D, Varagić VM. An improved gas chromatographic determination of valproic acid and valpromide in plasma. Pharm Acta Helv. 1992;67(8):237-40. PubMed PMID: 1409759.

20: Tasso SM, Moon SCh, Bruno-Blanch LE, Estiú GL. Characterization of the anticonvulsant profile of valpromide derivatives. Bioorg Med Chem. 2004 Jul 15;12(14):3857-69. PubMed PMID: 15210153.